Positive clinical research results for Sysmex Inostics OncoBEAM™-EGFR

Sysmex Inostics clinical research conducted at the Lyon Cancer Institute compared the performance of its OncoBEAM-EGFR to a next-generation sequencing assay in 183 non-small cell lung cancer patients with EGFR sensitizing mutations under first-line tyrosine kinase inhibitor therapy. The OncoBEAM-EGFR assay detected the p.T790M EGFR resistance mutation in 21.8% patients compared with 10.9%, and those that were positive only on the OncoBEAM assay had a mean allele fraction of just 0.13%. This report also used the OncoBEAM-EGFR assay in a circulating tumor cell spiking experiment, where the p.T790M mutation was detected in just 1.33 cells per mL of blood.
Principal investigator, Prof. Léa Payen, from the Hospices Civils de Lyon, said: “Given the high level of variability of tumor content in NSCLC patient plasma specimens and the great therapeutic utility of identifying an actionable EGFR mutation like T790M in a liquid biopsy specimen, it is of paramount importance to ensure mutation detectability at low allelic frequency. In our experience, plasma testing with OncoBEAM EGFR enabled us to detect the EGFR p.T790M mutation across a greater number of patients than NGS, representing a substantial proportion of patients that stand to benefit from targeted therapy.”